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Abstract
E12/E47 proteins (encoded by E2A gene) are members of the class I basic helix-loop-helix (bHLH) transcription factors (also
known as E proteins). E47 has been described as repressor of E-cadherin and inducer of epithelial-mesenchymal transition
(EMT). We reported previously that EMT mediated by E47 in MDCK cells occurs with a concomitant overexpression of Id1
and Id3 proteins. Id proteins belong to class V of HLH factors that lack the basic domain; they dimerise with E proteins and
prevent their DNA interaction, thus, acting as dominant negative of E proteins. Here, we show that E47 interacts with Id1 in
E47 overexpressing MDCK cells that underwent a full EMT as well as in mesenchymal breast carcinoma and melanoma cell
lines. By conducting chromatin immunoprecipitation assays we demonstrate that E47 binds directly to the endogenous E-
cadherin promoter of mesenchymal MDCK-E47 cells in a complex devoid of Id1. Importantly, our data suggest that both E47
and Id1 are required to maintain the mesenchymal phenotype of MDCK-E47 cells. These data support the collaboration
between E47 and Id1 in the maintenance of EMT by mechanisms independent of the dominant negative action of Id1 on
E47 binding to E-cadherin promoter. Finally, the analysis of several N0 breast tumour series indicates that the expression of
E47 and ID1 is significantly associated with the basal-like phenotype supporting the biological significance of the present
findings.
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Introduction
Epithelial-mesenchymal transition (EMT) is presently recog-
nised as a key process for tumour invasion and metastasis [1–3].
The hallmarks defining the EMT process are the loss of E-
cadherin mediated cell-cell adhesion and epithelial cell polarity
concomitant to the acquisition of mesenchymal markers and
increased motility and invasiveness [2–4]. Several transcriptional
factors, presently called EMT-TFs, have been identified as EMT
inducers, many of them also acting as direct E-cadherin repressors.
Among them, factors from the Snail (Snail1/Snail2), Zeb (ZEB1/
ZEB2) and bHLH (E47, Twist1, E2-2) families have been
described [1,2,5].
The molecular mechanisms underlying the action of the various
EMT-TFs are unequally known for Snail1 [6–11], Snail2 and
ZEB1 factors [12,13]. Much less is known on the mechanism of
bHLH factors participating in EMT [14].
Class I bHLH E12/E47 are two splice variants of the E2A (also
known as TCF3) gene product. E2A proteins regulate gene target
expression as homodimers or heterodimers with other bHLH
factors [15]. Id proteins (Id1-4), which lack the basic DNA binding
domain, associate with E2A proteins and prevent them from
binding to DNA [16]. A role for Id1 in mediating EMT-induced
by TGFbeta or other factors has been proposed. The action of Id1
in EMT appears to depend on its dominant negative action on
E2A factors in some systems [17,18], but mediated by interaction
with cytosolic/membrane proteins in other situations [19].
Interestingly, Id1 expression in breast cancer cells has been
correlated with poor prognosis and lung metastasis [20,21,22].
Moreover, mice lacking Id1/Id3 genes are resistant to tumour
neoangiogenesis and tumour cells failed to grow and/or metas-
tasize [23,24]. More recently, Id1 has been shown to be required
for self-renewal of adult neural stem cells and glioblastoma
tumours [25,26] and for the mobilization of endothelial precursor
cells to lung metastasis [27], further reinforcing the relevance of
Id1 in tumorigenesis.
Our previous studies demonstrated that E47 is a strong EMT
inducer and E-cadherin repressor [28,29], but the specific mech-
anisms mediating E47 actions and whether E47 expression is
required for EMT induction and/or maintenance of the
mesenchymal phenotype are still unknown. Our previous analysis
showed that Id factors, particularly Id1 and Id3, are strongly
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upregulated in MDCK cells stably expressing E47 or E2-2 factors
[30–32]. The present study analyse the interplay between E47 and
Id1 in E-cadherin repression and EMT. Our results reveal that E47
mediates E-cadherin transcriptional repression by direct interaction
with its promoter in a complex devoid of Id1. Sustained expression
of E47 and Id1 is required to maintain the mesenchymal
phenotype of MDCK-E47 cells and to preserve cell viability.
Remarkably, E47 as well as ID1 mRNAs are more frequently
expressed in basal-like breast carcinomas compared to non-basal
tumours supporting the participation of these proteins in defining
this aggressive breast tumour subtype.
Results
Id1 protein is upregulated and interacts with E47 in
MDCK-EGFP-E47 cells
To further characterize the E47/Ids interplay during EMT, and
because of the lack of reliable anti-E47 commercial antibodies for
immunoprecipitation assays, we generated stable transfectant
MDCK-EGFP-E47 cells. Extensive characterization of MDCK-
EGFP-E47 cells was performed in three independent clones that
showed almost complete repression of E-cadherin and the same
mesenchymal phenotype and properties than previously described
for MDCK-E47 cells including a full EMT conversion and
overexpression of Id1 and Id3 factors (Figure 1A; Figure S1).
To confirm the interaction between EGFP-E47 and Id proteins,
co-immunoprecipitation analyses were performed. EGFP-E47
protein strongly interacts with Id1 (Figure 1B) in MDCK-EGFP-
E47 cells. Confocal analysis in MDCK-EGFP-E47 cells showed
that Id1 protein was localized mainly in the nuclei; Id1 co-
localized with EGFP-E47 in the majority of cells (Figure1C, panels
f, h). Co-immunoprecitation analysis with Id3 showed a much
weaker interaction with EGFP-E47 compared to Id1 (data not
shown). Therefore, we focus our following studies on Id1. To
confirm E47-Id1 interaction, co-immunoprecipitation assays were
also performed in mesenchymal breast carcinoma MDA-MB435S
and melanoma A375P cells, previously shown to be E-cadherin
deficient and to overexpress E47 and Id1 factors ([29,31] and data
not shown). Results obtained indicated the interaction between
E47 and Id1 both cell lines (Figure 1D) thus confirming our
observations in MDCK-E47 cells.
Id1 is unable to overcome E-cadherin repression in
MDCK-E47 cells
Since Id proteins have been extensively described as dominant
negative of DNA binding of E47 and other class I bHLH factors
Figure 1. Id1 is upregulated and interacts in vivo with E47 in MDCK-EGFP-E47 cells. (A) Cell extracts derived from MDCK-EGFP and MDCK-
EGFP-E47 cells were analysed for expression of EGFP-E47, Id1 and Id3 proteins by Western blot; alpha-tubulin was used as loading control. Two
independent clones (#2, #6) generated after stable expression of EGFP-E47 in MDCK cells are shown. (B) Cell extracts derived from MDCK-EGFP and
MDCK-EGFP-E47 cells were immunoprecipitated with anti-Id1 antibodies and control IgGs and analysed by Western blotting with the indicated anti-
Id1 and anti-E2A antibodies. (C) Nomarski (a,b) and confocal immunofluorescence images (c-h) of MDCK-EGFP and MDCK-EGFP-E47 cells. Localization
of EGFP (c,g), EGFP-E47 (d,h) and Id1 (e,f) is shown. See the colocalization of Id1 with EGFP-E47 in the nuclei (merged image, h). Bars, 25 um. (D) Cell
extracts derived from MDA-MB435S (left panels) and A375P (right panels) cells were immunoprecipitated with anti-Id1 antibodies and control IgGs
and analysed by Western blotting with the indicated anti-Id1 and anti-E2A antibodies.
doi:10.1371/journal.pone.0059948.g001
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[15,16], we then analysed their effect on E47 repression of the E-
cadherin promoter. We first confirmed that E47 repression depends
on the proximal E-boxes, E-pal and E3, of the mouse E-cadherin
promoter (Figure 2A), in agreement with previous observations on
the dependence of the E-pal element for in vitro binding of E47
[28–33]. The E47-mediated repression of E-cadherin promoter in
MDCK cells was fully overcome by transient co-transfection with
Id1 (Figure 2B). We then analysed the effect of Id1 proteins in
MDCK cells stably expressing E47 with a complete EMT and
exhibiting very low E-cadherin promoter activity [29]. Transient
Id1 overexpression was unable to de-repress E-cadherin promoter
activity in MDCK-E47 cells (Figure 2C). Similar results were
obtained in MDCK-EGFP-E47 cells (unpublished data). More-
over, Id1 overexpression did not de-repress the basal activity of E-
cadherin promoter in MD-MDA435S and A375P cells (Figure S2).
Altogether, these results demonstrate that E-cadherin repression by
E47 is not sensitive to inhibition by Id1 protein once a full EMT is
achieved.
E47 interacts in vivo with the E-cadherin promoter in
complexes devoid of Id1
The interaction of E47 with the endogenous E-cadherin promoter
has not yet been studied at the chromatin level. To assess this
point, we performed chromatin immunoprecipitation (ChIP)
assays in MDCK-EGFP-E47 cells with anti-EGFP antibodies.
EGFP-E47 factor binds specifically to the endogenous E-cadherin
promoter in MDCK-EGFP-E47 cells compared to unspecific IgG
control (Figure 2D). To further characterize the E47 complexes
bound to the E-cadherin promoter, re-ChIP assays were carried out.
A sequential immunoprecipitation with anti-EGFP followed by
anti-Id1 antibodies showed the absence of Id1 binding to the E-
cadherin promoter in the chromatin fraction bound by EGFP-E47
(Figure 2D, re-ChIP, B fraction), while the unbound fraction from
the Id1 precipitates still retain a significant part of the endogenous
E-cadherin promoter (Figure 2D, re-ChIP NB fraction). The
specificity of the re-ChIP assay was further confirmed by parallel
re-ChIP assays with anti-EGFP and anti-Id1 antibodies (Figure
2E) that showed the ability of anti-EGFP to effectively precipitate
the remaining E-cadherin promoter from the Id1-ChIP fraction and
the complete absence of Id1 binding to the EGFP-E47 bound
fraction (Figure 2E, two most right lanes). These results indicate
that E47 interacts in vivo directly with the endogenous E-cadherin
promoter in MDCK-EGFP-E47 cells in complexes devoid of Id1.
Sustained E47 expression is essential for the
maintenance of EMT and tumour aggressiveness
One important and still unresolved question is whether
continued expression of E47 is necessary for maintenance or just
required for induction of EMT in MDCK cells, as reported for E2-
2 factors [32]. Since repeated attempts to knockdown E47 by
shE47 in MDCK cells were unsuccessful, we decided to silence
E47 expression by shRNA against EGFP in MDCK-EGFP-E47.
As a control, MDCK-EGFP cells were used to discard side-off
effects of the shEGFP. We first verified that EGFP-shRNA is
effectively knocking down EGFP and EGFP-E47 in all analysed
clones from MDCK-EGFP-shEGFP and MDCK-EGFP-E47-
shEGFP, respectively (Figure 3A, panels g,i,j, and 3B). Control
MDCK-EGFP cells after shEGFP remained with an epithelial
phenotype, expressing high levels of E-cadherin and other
epithelial markers and lacking Id1 expression (Figure 3A, B). In
contrast, EGFP-E47 silencing by shEGFP induced a remarkable
reversion to an epithelial phenotype in MDCK-EGFP-E47 cells
(Figure 3A, panels d,e), associated with re-expression of E-
cadherin and its re-localization at cell-cell contacts (Figure 3A
and B). Upregulation and membrane re-localization of the
epithelial markers beta-catenin and plakoglobin was also observed
(Figure 3A and B). Moreover, EGFP-E47 silencing promoted the
reorganization of the F-actin cytoskeleton from stress fibers and
lamellipodia-like structures to cortical actin filaments (Figure 3A
panels x,y, vs panel w). Significantly, EGFP-E47 silencing was
associated to almost complete suppression of Id1 overexpression in
MDCK-EGFP-E47-shEGFP clones (Figure 3B), further support-
ing the link between expression of E47, EMT and Id1 induction in
the MDCK cell system.
The relevance of E47 interference in the tumorigenic properties
of MDCK-EGFP-E47 cells was then analysed. EGFP-E47-
interfered clones were injected into nude mice, in parallel with
control MDCK-EGFP-E47 cells that exhibit similar tumorigenic
properties than previously reported for MDCK-E47 cells
[28,29,31]. All cell lines gave rise to tumours at all injection sites.
However, the shEGFP-E47 derived tumours grew at low rate with
an overall 50% to 85% reduction of tumour volume compared to
the tumours induced by control cells (Figure 3C). Tumours
induced by MDCK-EGFP-E47 cells were highly undifferentiated
spindle cell tumours, without evidence of epithelial differentiation
(Figure 3D, left). In contrast, tumours generated by MDCK-
EGFP-E47-shEGFP cells showed areas of glandular differentiation
surrounded by undifferentiated spindle cells (Figure 3D, right) or
were very small tumours (Figure 3C). Moreover, the MDCK-
EGFP-E47-shEGFP xenografts express E-cadherin at differentiat-
ed areas in contrast to the expected absence of E-cadherin
expression in control MDCK-EGFP-E47 tumours (Figure 3D,
lower panels).
These results indicate that sustained E47 expression is required
for the maintenance of the full phenotypic characteristics and
markers of EMT, including Id1 expression and for aggressive
tumorigenic properties of MDCK-E47 expressing cells.
Id1 expression is required for EMT induced by E47 and
cell survival
Once established that E47 is required to maintain the EMT
phenotype, we decided to study whether EMT also depends on
induction of Id1 in MDCK-E47 cells. To answer this point, we
knocked down Id1 in MDCK-EGFP-E47 cells by lentiviral
infection. Three independent shId1 lentiviral constructs were
tested and results obtained with shId1 9032 are shown (Figure 4).
It should be noted that the dog genome is only partially annotated
and shId1 sequences were selected based on one Id1 sequence with
strong human/dog homology. However, only shId1 9032 of the
three analysed shId1 lentivirus blocked efficiently endogenous Id1
in dog MCDK cells (data not shown). To discard side-off effects,
the action of the selected shId1 construct on MDCK-EGFP-E47
cells was compared with control lentivirus and with non-infected
cells. Efficient knockdown of Id1 was detected 48 h after infection
(about 90%) with no significant effect detected with the control
lentivirus (Figure 4A). After 48 h of infection, Id1 knockdown
induced a striking reversion to an epithelial-like phenotype in
MDCK-EGFP-E47-shId1 cells (Figure 4A, panel c) compared to
non-infected and control infected cells that remain fully mesen-
chymal (Figure 4B, panels a,b). The phenotypic Mesenchymal to
Epithelial (MET)-like reversion was accompanied by strong
organization of E-cadherin at cell-cell contacts in MDCK-
EGFP-E47-shId1 cells (Figure 4B, panel f) compared to parental
and control cells (Figure 4B, panels d,e). Knockdown of Id1 for
longer time periods induced a massive cell death; indeed, repeated
attempts to obtain stable infections with shId1 lentivirus were
unsuccessful. Analysis of the cell cycle indicated no major
E47 and Id Proteins Collaborate in EMT
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alterations in MDCK-EGFP-E47-shId1 cells compared to paren-
tal cells (Figure 4C). However, a dramatic increase in the sub-G0
population was detected in MDCK-EGFP-E47-shId1 cells indic-
ative of a high apoptotic rate compared to either parental and
control cells (Figure 4D).
Together, these results indicate that expression of Id1 is
required for maintenance of the mesenchymal phenotype after
EMT and cell viability of MDCK-EGFP-E47 cells.
E47 and ID factors expression in breast cancer
At present, very little is known about the expression of E47 and
IDs and their correlation with specific subtypes of human breast
carcinomas, although ID1 expression has been correlated with
poor prognosis, metaplastic tumours and lung metastasis in breast
carcinomas [20–22,34,35]. To investigate the biological signifi-
cance of E47 and ID factors in human breast cancer we analyzed
their expression together with markers defining the basal and non-
basal subtypes in unsupervised clustering analysis in a series of 97
sporadic N0 breast carcinomas profiled by Vant Veer et al. [36].
Figure 2. E47 represses E-cadherin by direct binding to the endogenous promoter in complexes devoid of Id1. (A) Dependence of E47
repression of E-cadherin promoter on proximal E-boxes. HEK293T cells transiently co-transfected with 200 ng of the proximal wild type mouse E-
cadherin-Luciferase promoter (2178/+92 bp) or point mutants in the proximal E-boxes (E-pal +/2 E-box3) and 10 ng of CMV-beta-gal plasmid in the
presence of 50 ng of pcDNA3-E47 (dark grey bars) or control pcDNA3 (light grey bars) vectors, as indicated. Differences between the E47 mediated
repression of the mutants versus the wild type promoter were statistically analysed by t-Student test (***p,0.001). (B) and (C) E-cadherin promoter
activity in MDCK (B) and MDCK-CMV and MDCK-E47 (C) cells transiently co-transfected with 200 ng of the proximal mouse E-cadherin-Luciferase
promoter (2178/+92 bp) and 20 ng of TK-Renilla (B) or 10 ng of CMV-beta-gal (C) plasmids, in combination with the indicated amounts of pcDNA3-
E47 and/or pcDNA3-Id1 vectors. RLU is normalized to that detected with empty pcDNA3 vector (A, B) or in control MDCK-CMV cells (C, left); results
represent the mean of at least two independent experiments +/2 s.d. (D) and (E) Chromatin immunoprecipitation (ChIP) assays of EGFP-E47 at the
endogenous E-cadherin promoter in MDCK-EGFP-E47 cells. (D) ChIP assays were first performed with an antibody specific for EGFP or control IgG and
the bound fraction analysed for endogenous E-cadherin promoter sequences (dCdh1) (left three lanes), followed by re-ChIP with anti-Id1 antibodies
(IP2) and analyses of the bound (B) and unbound (NB) fractions for E-cadherin promoter sequences (dCdh1) (right two lanes). The input fraction (1/
100) is shown at the left. Quantification of the amplified endogenous E-cadherin promoter compared to the input fraction (1/100) is shown in the
lower panel. (E) ChIP assays were first performed with anti-EGFP (IP1) followed by re-ChIP (IP2) with anti-EGFP or anti-Id1 antibodies, as indicated,
followed by analyses of the bound (B) and unbound (NB) fractions for E-cadherin promoter sequences (dCdh1). Input (1/100) and control IgG ChIP are
shown on the left two lanes. Quantification of the amplified endogenous E-cadherin promoter compared to the input fraction (1/100) is shown in the
lower panel.
doi:10.1371/journal.pone.0059948.g002
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As shown in Figure 5A, tumours were sub-classified into two
main clusters, indicating that TCF3 (E47/E12) and ID genes are
differentially expressed among breast carcinomas. Attending to the
markers defining tumour subgroups, the right cluster (yellow bar)
contained the hormone-receptor-negative tumours; according to
the low expression of ESR, PGR, ERBB2 and luminal keratins
(KRT8 and KRT19) and high expression of basal keratins (KRT5,
KRT14, KRT17) this subgroup corresponds to the basal-like
tumours. The left-handed cluster (purple bar) includes the non-
basal tumours (luminal and ErbB2+). In this dataset, positive
TCF3, ID1 and ID4 expression were more frequent (Chi-square
test, p = 0.033, p,0.001, and p,0.001, respectively) in the basal-
like tumours (Figure 5B). Moreover, TCF3, ID1 and ID4
expression showed a strong association with the expression of
basal markers, such as CK14, CK17, and P-cadherin (Table S1).
These results agree with and complement previous studies on ID1
protein expression in metaplastic and triple negative breast cancer
tumours [21,34]. Furthermore, the analysis of TCF3 expression in
several breast carcinomas dataset [37–40] showed that TCF3
upregulation associated to the basal-like phenotype (Figure 5C,
upper) and exemplified in dedifferentiated breast carcinoma
MDA-MB435 cells (Figure 1D). In addition, TCF3 upregulation
was associated to shorter overall survival in the Miller’s series [39]
(Figure 5C, bottom). Taken together, these results suggest TCF3 as
a new marker of basal-like breast tumors and support the interplay
between E47 and ID factors in this tumour subtype.
Discussion
Class I bHLH E2A factors (E12/E47) have been previously
shown to promote E-cadherin repression and to induce EMT and
invasive, tumorigenic and angiogenic or fibrotic properties when
expressed in epithelial cells [17,28,29,31,41]. However, the
mechanisms underlying E-cadherin repression and the specific role
of E12/E47 in EMT have not yet been elucidated. We report here
Figure 3. E47-silencing in MDCK-EGFP-E47 cells induces a MET process, downregulation of Id1 and reduction of tumour growth. (A)
Phase contrast images (a-e) and immunofluorescence images (f–y) of the indicated cell lines showing localization of EGFP (f,g), EGFP-E47 (h–j),
Ecadherin (k–o), beta-catenin (p–t) and F-actin organization (u–y). Nuclei were stained with DAPI (k–y). Black bar, 60 um (a–e); white bars, 25 um (f–y).
(B) Western blot analyses of epithelial markers and Id1 in the indicated cell lines; alpha-tubulin was used as loading control. Two (#N, #P) and five
independent clones (#N, #M, #L, #O, #P) generated after stable expression of shEGFP into MDCK-EGFP-E47 (clone #6) cells are shown in A and B,
respectively. (C) The tumorigenic potential of MDCK-EGFP-E47#6 and MDCK-EGFP-E47-shEGFP#N and #P cells was analysed by subcutaneous
injection into nude mice. ANOVA analysis: *p,0.05; **p,0.01; ***p,0.001. (D) Histology (upper panels) and immunohistochemical analysis for E-
cadherin (lower panels) of tumours induced by MDCK-EGFP-E47#6 (left) and MDCK-EGFP-E47-shEGFP#N cells (right). Amplification x20. Insets show
amplified fields at x40.
doi:10.1371/journal.pone.0059948.g003
E47 and Id Proteins Collaborate in EMT
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e59948
that E47 transcriptional repressor binds directly to the E-cadherin
promoter in MDCK cells stably expressing E47 factor. We also
show that continued expression of E47 and Id1 is necessary for
maintenance of EMT in the MDCK-EGFP-E47 cell system.
Consistent with the dominant negative action of Ids on bHLH
factors [15,16] we show that Id1 protein efficiently overcome E47-
induced repression of E-cadherin promoter in transient co-
transfection assays in epithelial MDCK cells, similar to previously
reported for Id3 [17]. However, overexpressed Id1 protein is
unable to overcome E47-dependent repression of E-cadherin
expression in mesenchymal MDCK-E47 cells; a similar situation
was observed for Id2 and Id3 (unpublished data). Indeed, the
ChIPs assays show that E47 binds to the endogenous E-cadherin
promoter of MDCK-EGFP-E47 cells in complexes devoid of Id1.
Nonetheless, this situation occurs despite the physical interaction
between E47 and Id1 detected in mesenchymal MDCK-EGFP-
E47 cells. The E47/Id1 interaction and inability of Id1 to
reactivate the E-cadherin promoter was further confirmed in E47-
expressing basal-like breast carcinoma and melanoma cells. One
possible explanation to reconcile these apparently contradictory
findings is that post-translational modifications might regulate E47
transcriptional activity, as previously described for site-specific
phosphorylation and/or covalent disulfide bond dimerization [42-
45]; such modifications in a subset of E47 molecules might
attenuate their interaction with Id1 and allow E47 binding to the
E-cadherin promoter in absence of Id1. It is tempting to speculate
that this subset of E47 molecules can act as active homodimers
promoting E-cadherin repression; in fact, our previous in vitro band-
shift and in vivo yeast-one-hybrid analysis indicated that E47
interacts with the mouse E-cadherin promoter as a homodimer
[29,33]. Another possibility is the interaction of E47 with tissue-
specific class II bHLH factors [15]. One potential candidate is
Twist1, another EMT inducer [46]; we tested this hypothesis, but
we could not find any functional E47/Twist1 interaction in E-
cadherin promoter assays (unpublished data) in line with recent data
suggesting an indirect role of Twist1 in E-cadherin repression [3,47].
Alternatively, the presence of activating E proteins sequestered by
Id1 induction in the presence of E47 could be another option.
Figure 4. Id1 knockdown in MDCK-EGFP-E47 cells induces a partial MET and impairs cell survival. (A) Western blot analysis of Id1
expression in MDCK-EGFP-E47 cells after 48 h infection with shId1 or control lentivirus (EV), compared to non-infected (EGFP-E47) and control MDCK-
CMV (CMV) cells; alpha-tubulin was used as loading control. (B) Phase contrast (upper panels) and confocal immunofluorescence images of E-
cadherin (lower panels) of EGFP-E47-shId1 (right) and EGFP-E47-EV control (middle) cells 48 h after lentiviral infection; non infected MDCK-EGFP-E47
cells (left) are shown as additional control. Nuclei were stained with DAPI; bars, 50 um. (C) Cell cycle analysis of the indicated cell lines by propidium
iodide staining and FACS analysis. (D) Apoptosis rate of the indicated cells determined by the sub-G0 population. Results in C and D represent the
mean +/2 s.d. on triplicate samples.
doi:10.1371/journal.pone.0059948.g004
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Although further studies are clearly required to clarify the
mechanism, in the present scenario, we favour the hypothesis
that a subset of E47 molecules with potential post-translational
modifications could be responsible of E-cadherin repression likely in
homodimeric form.
The present data also provide evidence for a strong link between
E47 and Id1 in EMT. Sustained expression of E47 is required to
maintain the mesenchymal phenotype after EMT, in contrast to
the behaviour of E2-2 factors that act as EMT-inducers but are
dispensable for maintenance of EMT [32]. Significantly, the MET
induced by E47-silencing in MDCK-EGFP-E47 cells is associated
to strong downregulation of Id1. Moreover, Id1 knockdown also
induces a MET-like process in MDCK-EGFP-E47 cells, indicating
that expression of Id1 is indeed required for maintenance of EMT
induced by E47 and, importantly, for cell survival. These results
agree with the pleiotropic effect of Id1 on cell proliferation and
survival, partly independent of E2A proteins [16,48], and support
the collaboration between E47 and Id1 in EMT beyond E-cadherin
repression. Interestingly, Id1 is induced by additional EMT-TFs,
like Snail1, Snail2 and E2-2A/B [30-32], further supporting its
participation in maintenance of EMT. Whether the specific action
of Id1 in EMT maintenance is dependent of its interaction with
other nuclear, cytosolic or membrane proteins remains to be
established.
Many studies highlight distinct roles for Id proteins in
tumorigenesis, invasiveness and metastasis in epithelial, endothelial
and hematopoietic cells [16]. Furthermore, ID1 overexpression
has been associated with malignancy, poor clinical outcome or
lung metastasis in different tumour types [20–22,25,34,35,49].
Overexpression of E47 in some tumours and cell lines has also
been reported [29,50,51]. Interestingly, our analysis of E47 (TCF3)
and IDs expression in the N0 breast carcinoma series profiled by
Van’t Veer et al. [36] indicates that the expression of E47 and ID1
is significantly associated with the basal-like phenotype in sporadic
tumours, in agreement with previous observations on ID1 protein
expression [21]. Overexpression of ID4 was also associated with
basal-like tumours, in agreement with a recent report on ID4
protein overexpression in triple negative breast tumours (TNBC)
[52], and also detected in the vant’ Veer series (Figure 5B).
Rrecent studies have highlighted the connection between ID4
induction and downregulation of BRCA1 in TNBCs [53] as well
as with p53 mutation in estrogen receptor negative (ER-) breast
tumours [54] that might contribute to chemoresistance of p53
mutant breast tumours [55]. Interestingly, E47 has been also
reported to contribute to doxorubicin chemoresistance [56].
Upregulation of Id4 transcripts were also previously observed in
MDCK cells overexpressing E47, although to a lower extent than
Id1 [31], supporting also the correlation between ID4 and TCF3
upregulation in basal breast tumours. Whether ID1 and ID4 play
non-redundant or complementary actions on EMT and/or the
basal phenotype and chemoresistance of breast tumours remains
to be established in future studies. Importantly, our present study
Figure 5. E47 and ID factors are preferentially expressed in basal-like breast carcinomas. (A) Unsupervised hierarchical clustering of the
vant’Veer dataset (ref. 36) for the expression of the indicated basal and luminal markers, together with estrogen (ESR1) and progesterone receptors
(PGR) and ErbB2, identifies two clusters of basal (yellow) and non-basal (purple) tumours. Increased TCF3 and ID1/ID4 transcripts cluster with the
basal-like subgroup. (B) Association between the expression of TCF3 and ID1/ID4 with the basal-like phenotype in the vant Veer’s dataset. To validate
the association among specific genes and/or tumour subgroups, each variable was categorized using the percentile 75 value as the cut-off. (C)
Overexpression of TCF3 associated to basal-like breast tumours (upper) and to decreased overall survival (bottom) in the indicated public datasets.
doi:10.1371/journal.pone.0059948.g005
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detected TCF3 upregulation in basal-like tumours in several
additional public datasets and associated to poor survival (Figure
5C), reinforcing previous observations indicating that basal-like
carcinomas are the most likely candidate breast tumours to suffer
EMT processes [57-59]. A few pathways and molecules have been
so far implicated in the regulation of epithelial plasticity in basal-
like tumours, including the Wnt signaling, Forkhead 1 factor
FOXC2, and lysyl oxidase-like 2 (LOXL2) [60–63]. The evidences
here presented suggest that additional genes such as TCF3 and ID1
could also mediate EMT in basal-like carcinomas. Furthermore,
our previous observation that upregulation of TCF8 (ZEB1) occurs
in metastatic and more undifferentiated breast tumours of the
Vant Veer’s series [64] suggest a potential link between E47/ID1
or ID4 and TCF8 expression in undifferentiated basal-like
tumours. Although further studies are required, our present
observations on the E47 and ID1 expression profile in the N0
breast carcinoma series provide biological basis to the interplay
between E47 and ID1 here described.
Materials and Methods
Plasmid constructs
Enhanced green fluorescent protein EGFP-E47 construct was
generated by PCR using the full-length mouse E47 cDNA as
template [29] with the following primers (restriction sites indicated
in bold): 59-CTCGAGGGATGATGAACCAGTCTCA-39 (for-
ward) and 59-GAATTCGGCTCACAGGTGCCCGGCTGGGT
-39 (reverse). The PCR product was cloned in the pEGFP-C1
vector (Clontech, Mountain View; CA). Mouse Id1 construct
(pcDNA3-Id1) was provided by Dr. M. Saitoh (Tokio University,
Japan).
Cell culture and gain of function studies
MDCK-II (Madin Darby canine kidney type II) and human
HEK293T (human embryonic kidney 293 transformed with T-
antigen), MDA-MB435S whose origin has been firmly established
as dedifferentiated breast carcinoma [65,66] and melanoma
A375P cells were obtained from the American Type Cell Culture
(ATCC) (LGC Standards-SLU; Barcelona, Spain) and cultured as
previously described [29]. Stable transfectants were obtained from
parental MDCK-II (Madin Darby canine kidney type II) cells
(obtained from the ATCC) (LGC Standards-SLU; Barcelona,
Spain) after transfection with pEGFP-C1-E47, or the correspond-
ing control vector, using Lipofectamine (Invitrogen; Carlsbad,
CA). Cells were grown as previously described [67] in the presence
of G418 (400 mg/ml; Gibco; Madrid, Spain) for 3–4 weeks and
individual clones isolated with cloning rings. At least ten
independent clones were isolated and results from two represen-
tative clones from each setting are shown. The origin and
characterization of MDCK-CMV and MDCK-E47 cells has been
previously described [29,67].
RNA interference
The generation of shRNA containing specific oligonucleotide
sequences against EGFP cloned into the pSuperior-Puro vector
(Oligoengine; Seattle, WA) was previously described [30].
MDCK-EGFP and MDCK-EGFP-E47 (clone #6) cells were
transfected with shEGFP vector using Lipofectamine 2000
(Invitrogen) and sorted using a FACSVantage SE (Becton
Dickinson; Madrid, Spain) to obtain populations with more than
90% EGFP-negative cells. At least ten clones were isolated from
each pool by limited dilution and results from two to five
independent clones from each setting are shown.
Lentiviral infection
Id1 knockdown was performed by lentiviral infection with
specific shRNA vectors (TRCN0000019032; Sigma-Aldrich; St
Louis, MO). Briefly, HEK293T cells were transfected with a mix
containing VSV-G envelope and DR 8.91 packaging genes and
either control vector (pLKO: EV) or Id1 specific shRNA using
Lipofectamine 2000 and incubated for 48 h. MDCK-EGFP-E47
cells were infected with the lentiviral supernatant with polybrene
(8 ng/ml) during 48 h.
E-cadherin promoter assays
The activity of the mouse E-cadherin (Cdh1) promoter on
HEK293T, MDCK and MDCK-derived clones, MDA-MB435S
and A375P cells was determined as described [67]. Mutants in the
E-pal and/or E3-box were previously described [32]. Statistical
analyses were performed by the two paired t-Student’s test.
Northern Blotting
15 to 30 ug of total RNA from the different cell lines were
analysed in Northern blot using a specific P32-cDNA Cdh1 probe
as described [30].
Cell extracts, Western blot analysis and
immunoprecipitations
Whole cell extracts, lysates, immunoprecipitation conditions
and Western blot analyses were performed as described
[11,12,67]. The primary and secondary antibodies used are
described in Table S2.
Chromatin immunoprecipitation (ChIP) and Sequential
ChIP assays
ChIP assays were performed in MDCK-EGFP-E47 (clone #6)
cells, using formaldehyde before sonication, as described [11,32].
For detection of interaction between the tagged factors and the
endogenous Cdh1 promoter, an anti-EGFP antibody (Molecular
Probes; Grand Island, NY) or unspecific rabbit IgG (Jackson
ImmunoResearch Laboratories; Suffolk, UK) were used. A 215 bp
fragment of the dog Cdh1 promoter (–85/+130) was amplified
using the primers and amplification conditions previously
described [32]. For re-ChIP assays, the immune complexes were
harvested with elution buffer (TE 1X, 2% SDS, 15 mM DTT and
protease inhibitors), diluted 1:10 with dilution buffer (10 mM Tris-
HCl [pH 8], 150 mM NaCl, 1 mM EDTA, 0.01% SDS, 0.5%
Nonidet P-40 and protease inhibitors), and the steps of the ChIP
assay repeated with a second round of immunoprecipitation using
anti-EGFP (Molecular Probes) or anti-Id1 (Santa Cruz; California,
CA) antibodies.
Cell cycle and apoptosis assays
Cell cycle analysis was performed by propidium iodide staining.
Semi-confluent cells were trypsinized and washed twice with PBS,
fixed with cold 70% ethanol, washed, resuspended in PBS with
10 ug/ml of propidium iodide, and analysed in a FACScanI
(Becton Dickinson) using a ModFIT LT v3.2 software. Assays
were performed on triplicate samples.
Immunofluorescence
Immunofluorescence analysis and F-actin stain was performed
as described [67]. The primary and secondary antibodies used are
described in Table S2. Preparations were visualized using a Zeiss
Axiophot or a Leica confocal TCSSP2 microscope.
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Induction of xenografted tumours and histological
studies
Subconfluent cells were trypsinised, washed and resuspended at
16107 cells/ml in PBS. 16106 cells were injected into the flanks of
8-week old male BALB/c nude mice (Charles River; Wilmington,
MA). Tumours were measured every 3–4 days using a calliper by
determination of the two orthogonal external diameters; statistical
comparisons were made by ANOVA analysis. Mice were
sacrificed when the tumours reach 0.1 cm3 size; tumours were
surgically excised and processed for histology as described [67].
Mice were housed and maintained under specific pathogen-free
conditions and used in accordance with institutional guidelines
and approved by the Use Committee for Animal Care. The
protocol was approved by the Committee on the Ethics of the
University Autonomous of Madrid (UAM. Permit Number: CEI-
25-587) and Spanish National Research Council (CSIC), accord-
ing with present Spanish law (R.D. 1201/2005, 10th October,
BOE 21st October 2005). All animals were monitored for ill effects
and sacrificed at 32 days post-injection; all efforts were made to
minimize suffering according to UAM/CSIC guidelines. A
minimum of 4 tumours from each cell line were generated and
analysed by histology and immunohistochemistry.
Human breast cancer expression data set and statistical
analysis
Microarray and clinical data from 97 sporadic breast tumours,
reported by van’t Veer et al. [36] were used. The sporadic samples
included primary invasive carcinoma ,5 cm (T1 or T2), with no
axillary lymph node metastases (N0). To classify the breast samples
according to basal and non-basal (luminal and ErbB22+)
phenotypes, we extracted the log ratio values of ESR1 (estrogen
receptor), PGR (progesterone receptor), ERBB2, and luminal (CDH1,
KRT8, and KRT19) and basal markers (CDH3, KRT5, KRT14, and
KRT17) present in the Vant Veer dataset; in addition, we select the
TCF3 (E47) and ID (ID1–4) factors expression. Hierarchical cluster
analysis was performed assuming euclidean distances between
genes. For significance associations Yates correction or Fisher’s
exact test were used. To evaluate TCF3 association to breast
carcinoma subtypes, several independent dataset of carcinoma
series were also analysed [37–40]. The clinical data were obtained
from the ICR database (www.rock.icr.ac.uk). TCF3 expression
values were categorized using upper quartile (25% against rest).
Supporting Information
Figure S1 Stable expression of EGFP-E47 in MDCK cells
triggers a complete EMT. (A) Phase contrast (a–c) and
immunofluorescence (d–l) images of the indicated cell lines for
EGFP (d), EGFP-E47 (e,f), E-cadherin (g–i) and vimentin (j–l).
Nuclei were stained with DAPI (g–l). Bars, 60 mm (a–c); 25 mm
(d–l). (B and C). Western blot (B) and Northern blot analysis (C)
analyses of the indicated markers in E47 expressing cells and
controls. alpha-tubulin and GAPDH were used as loading
controls.
(TIF)
Figure S2 E-cadherin promoter activity in A375P (left)
and MDA-435S (right) cells transiently cotransfected
with 200 ng of the proximal mouse E-cadherin promoter
and increasing amounts of Id1 and 10 ng of CMV-beta-
gal. RLU is normalized to activity detected in the presence of
pcDNA3. Results represent the mean +/- s.d. of three indepen-
dent experiments performed on triplicate samples.
(TIF)
Table S1 Association of TCF3 positive expression with
basal and luminal markers in N0 breast tumours. The
categorical expression of progesterone receptor (PGR), estrogen
receptor (ESR1), ERBB2, and basal and luminal markers in the
van’t Veer’s dataset (ref. 38) is shown.
(DOC)
Table S2 Antibodies used in Western-blot, immunoflu-
orescence immunoprecipitation and IHQ assays.
(DOC)
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